These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37088804)

  • 41. Somatic mismatch repair testing in evaluation of Lynch syndrome: The gap between preferred and current practices.
    Williams D; Vilar E; Shakrukh Hashmi S; Choates M; Noblin S; Mork M
    J Genet Couns; 2020 Oct; 29(5):728-736. PubMed ID: 31896172
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Integrative analysis of hereditary nonpolyposis colorectal cancer: the contribution of allele-specific expression and other assays to diagnostic algorithms.
    De Lellis L; Aceto GM; Curia MC; Catalano T; Mammarella S; Veschi S; Fantini F; Battista P; Stigliano V; Messerini L; Mareni C; Sala P; Bertario L; Radice P; Cama A
    PLoS One; 2013; 8(11):e81194. PubMed ID: 24278394
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Utility of germline multi-gene panel testing in patients with endometrial cancer.
    Karpel HC; Chern JY; Smith J M; Smith A J; Pothuri B
    Gynecol Oncol; 2022 Jun; 165(3):546-551. PubMed ID: 35483985
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterisation of heterozygous
    Wang Q; Leclerc J; Bougeard G; Olschwang S; Vasseur S; Cassinari K; Boidin D; Lefol C; Naïbo P; Frébourg T; Buisine MP; Baert-Desurmont S;
    J Med Genet; 2020 Jul; 57(7):487-499. PubMed ID: 31992580
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer.
    Lu KH; Schorge JO; Rodabaugh KJ; Daniels MS; Sun CC; Soliman PT; White KG; Luthra R; Gershenson DM; Broaddus RR
    J Clin Oncol; 2007 Nov; 25(33):5158-64. PubMed ID: 17925543
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Somatic tumor testing implications for Lynch syndrome germline genetic testing.
    Barrus K; Purington N; Chun N; Ladabaum U; Ford JM
    Cancer Genet; 2022 Jun; 264-265():16-22. PubMed ID: 35286930
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Frequency of rearrangements in Lynch syndrome cases associated with MSH2: characterization of a new deletion involving both EPCAM and the 5' part of MSH2.
    Pérez-Cabornero L; Infante Sanz M; Velasco Sampedro E; Lastra Aras E; Acedo Becares A; Miner Pino C; Durán Domínguez M
    Cancer Prev Res (Phila); 2011 Oct; 4(10):1556-62. PubMed ID: 21791569
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lynch Syndrome Identification in Saudi Cohort of Endometrial Cancer Patients Screened by Universal Approach.
    Bu R; Siraj AK; Parvathareddy SK; Iqbal K; Azam S; Qadri Z; Al-Rasheed M; Haqawi W; Diaz M; Alobaisi K; Annaiyappanaidu P; Siraj N; AlHusaini H; Alomar O; Al-Badawi IA; Al-Dayel F; Al-Kuraya KS
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293153
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of suspected Lynch syndrome patients carrying BRCA and BRCA-like variants with Lynch syndrome probands: Phenotypic characteristics and pedigree analyses.
    Xu Y; Li C; Wang Z; Liu F; Xu Y
    Mol Genet Genomic Med; 2020 Aug; 8(8):e1359. PubMed ID: 32548945
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of paired tumor and germline testing in evaluation of patients with Lynch-like syndrome in a large integrated healthcare setting.
    Carwana H; Hoodfar E; Bergoffen J; Li D
    Fam Cancer; 2021 Jul; 20(3):223-230. PubMed ID: 33215268
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
    Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
    J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical implications of genetic testing in familial intermediate and late-onset colorectal cancer.
    Djursby M; Hansen TVO; Wadt KAW; Madsen MB; Berchtold LA; Lautrup CK; Markholt S; Jensen UB; Krogh LN; Lundsgaard M; Gerdes AM; Nilbert M; Therkildsen C
    Hum Genet; 2022 Dec; 141(12):1925-1933. PubMed ID: 35904628
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Next Generation Sequencing in Molecular Diagnosis of Lynch Syndrome - a Pilot Study Using New Stratification Criteria.
    Kašubová I; Holubeková V; Janíková K; Váňová B; Sňahničanová Z; Kalman M; Plank L; Lasabová Z
    Acta Medica (Hradec Kralove); 2018; 61(3):98-102. PubMed ID: 30543514
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lynch or not Lynch? Is that always a question?
    Colas C; Coulet F; Svrcek M; Collura A; Fléjou JF; Duval A; Hamelin R
    Adv Cancer Res; 2012; 113():121-66. PubMed ID: 22429854
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory.
    van Lier MG; Wagner A; van Leerdam ME; Biermann K; Kuipers EJ; Steyerberg EW; Dubbink HJ; Dinjens WN
    J Cell Mol Med; 2010 Jan; 14(1-2):181-97. PubMed ID: 19929944
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comprehensive mismatch repair gene panel identifies variants in patients with Lynch-like syndrome.
    Xavier A; Olsen MF; Lavik LA; Johansen J; Singh AK; Sjursen W; Scott RJ; Talseth-Palmer BA
    Mol Genet Genomic Med; 2019 Aug; 7(8):e850. PubMed ID: 31297992
    [TBL] [Abstract][Full Text] [Related]  

  • 57. POLE and POLD1 germline exonuclease domain pathogenic variants, a rare event in colorectal cancer from the Middle East.
    Siraj AK; Bu R; Iqbal K; Parvathareddy SK; Masoodi T; Siraj N; Al-Rasheed M; Kong Y; Ahmed SO; Al-Obaisi KAS; Victoria IG; Arshad M; Al-Dayel F; Abduljabbar A; Ashari LH; Al-Kuraya KS
    Mol Genet Genomic Med; 2020 Aug; 8(8):e1368. PubMed ID: 32567205
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Loss of MSH2 and MSH6 due to heterozygous germline defects in MSH3 and MSH6.
    Morak M; Käsbauer S; Kerscher M; Laner A; Nissen AM; Benet-Pagès A; Schackert HK; Keller G; Massdorf T; Holinski-Feder E
    Fam Cancer; 2017 Oct; 16(4):491-500. PubMed ID: 28528517
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Germ-line variants identified by next generation sequencing in a panel of estrogen and cancer associated genes correlate with poor clinical outcome in Lynch syndrome patients.
    Jóri B; Kamps R; Xanthoulea S; Delvoux B; Blok MJ; Van de Vijver KK; de Koning B; Oei FT; Tops CM; Speel EJ; Kruitwagen RF; Gomez-Garcia EB; Romano A
    Oncotarget; 2015 Dec; 6(38):41108-22. PubMed ID: 26517685
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MLH1 epimutation is a rare mechanism for Lynch syndrome: A case report and review of the literature.
    Zyla R; Graham T; Aronson M; Velsher L; Mrkonjic M; Turashvili G
    Genes Chromosomes Cancer; 2021 Sep; 60(9):635-639. PubMed ID: 33934415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.